Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Cardiff Oncology, Inc. (CRDF)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 | $366,000 | $244,632 | $378,325 | $505,404 | $381,072 | $312,812 | $280,178 | $259,246 | $450,404 | $257,696 | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $35.3M | $36.9M | $32.9M | $27.1M | $17.4M | $11.2M | $11.2M | $8.2M | $7.9M | $15.0M | $10.6M | $6.7M | $3.9M | $1.9M | $910,685 | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $49.6M | $49.3M | $45.9M | $40.3M | $29.2M | $19.5M | $16.9M | $17.4M | $26.1M | $40.5M | $25.6M | $15.2M | $10.9M | $5.3M | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$49.0M | −$48.7M | −$45.4M | −$39.9M | −$28.9M | −$19.1M | −$16.7M | −$17.1M | −$25.6M | −$40.1M | −$25.3M | −$14.9M | −$10.7M | −$4.8M | −$3.0M | — | — | — | — | — | — | — | — | — | — | — |
| EBITDAderived | −$48.6M | −$48.2M | −$45.0M | −$39.7M | −$28.4M | −$18.6M | −$16.2M | −$16.2M | −$24.3M | −$39.1M | −$24.9M | −$14.7M | −$10.6M | −$4.8M | −$3.0M | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$45.9M | −$45.4M | −$41.4M | −$38.7M | −$28.3M | −$19.3M | −$16.4M | −$16.5M | −$24.9M | −$39.2M | −$27.5M | −$14.3M | −$11.8M | −$11.6M | −$2.2M | −$5.4M | −$2.5M | −$5.2M | −$4.7M | −$7.1M | −$7.8M | −$5.4M | −$383,021 | −$481,609 | −$524,224 | −$267,599 |
| Basic EPSper diluted share | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | -$1.08 | -$2.80 | -$8.26 | -$51.76 | -$1.30 | -$1.05 | -$0.76 | -$0.70 | -$0.89 | -$0.23 | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | -$1.08 | -$2.80 | -$8.26 | -$51.76 | -$1.37 | -$1.21 | -$0.88 | -$0.70 | -$0.89 | -$0.23 | — | — | — | — | — | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 | Mohindru ManiChief Executive Officer | BuyCommon Stock | 24.7K | $1.21 | $29.9K | 24.7K |
| Jun 18, 2026Form 4 | PACE GARY WDirector | BuyCommon Stock | 30.0K | $1.22 | $36.6K | 1.36M |
| Jul 30, 2025Form 4 | PACE GARY WDirector | BuyCommon Stock · indirect | 15.0K | $2.45 | $36.8K | 1.35M |
| Jul 30, 2025Form 4 | PACE GARY WDirector | BuyCommon Stock | 275.0K | $2.45 | $673.8K | 1.33M |
| Dec 18, 2024Form 4 | Levine James E.Chief Financial Officer | BuyCommon Stock · indirect | 2.4K | $5.00 | $12.0K | 67.7K |